EXAS
HealthcareExact Sciences Corporation
$101.61
$-0.13 (-0.13%)
Jan 5, 2026
Price History (1Y)
Analysis
Exact Sciences Corporation is a healthcare company that operates in the diagnostics and research industry. It has a significant scale with a market capitalization of $19.28 billion and annual revenues of $3.08 billion. The company's financial health is notable for its high debt levels, with a debt-to-equity ratio of 101.34. However, it also has a substantial cash balance of $1.00 billion. Exact Sciences Corporation reported a net loss of $986 million in the trailing twelve months and an operating margin of -0.1%. The company's gross margin is relatively high at 69.4%, but its profit margin is negative at -32.0%. The valuation of Exact Sciences Corporation appears to be high, with a forward price-to-earnings ratio of 90.89. Its revenue growth has been strong, increasing by 20.1% year-over-year. The company's beta is 1.41, indicating that its stock price may be subject to higher volatility compared to the market as a whole.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Exact Sciences Corporation
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
Visit website →Key Statistics
- Market Cap
- $19.28B
- P/E Ratio
- N/A
- 52-Week High
- $102.66
- 52-Week Low
- $38.81
- Avg Volume
- 5.40M
- Beta
- 1.41
Company Info
- Industry
- Diagnostics & Research
- Exchange
- NCM
- Country
- United States
- Employees
- 6,900